Sentence examples for flare score from inspiring English sources

A two-sample t test was used for the comparisons in aqueous cells score and flare score at baseline between two groups.

The secondary variables were aqueous cell score, aqueous flare score, cell count, flare value, and the treatment failure rate (the percentage of subjects with either an aqueous cell score or an aqueous flare score of 3 or more, or an ocular pain score of 4 or more) at each postoperative visit.

The primary efficacy variables were the percentage of patients cured at postoperative day 14 visit (cure defined as aqueous cells score + aqueous flare score = 0) and the percentage of patients who were pain free at all postoperative visits.

The primary efficacy variables were the cure rate (the percentage of subjects with an aqueous cell score + aqueous flare score = 0) at day 14 after surgery and the ocular pain-free rate (the percentage of subjects with an ocular pain score of 0) at all postoperative visits.

Significant intergroup differences were observed in the cell score on day 7 and subsequent visits (P < 0.0001 for days 7 and 14) and in the flare score on day 3 and subsequent visits (P = 0.0041 for day 3 and P < 0.0001 for days 7 and 14) (Tables 9 and 10).

In contrast, no marked decrease was observed in either the cell or flare scores in the placebo group.

The analysis of aqueous cells score, flare scores, cell counts, and flare value was conducted with a repeated measures analysis of variance at postoperative visits.

In the nepafenac group, cell scores and flare scores measured at each postoperative visit decreased as time elapsed after surgery, showing the suppressive effect of nepafenac on postoperative inflammation.

Many participants were unaware of foods that may lead to a gout flare (mean score of 3.4 [±2.3]; range 0 10; alpha = 0.68) (Table 3).

Participants with tophi reported higher frequency of gout flares, pain scores, patient global assessment scores, and HAQ scores.

Renal disease activity was assessed using the renal component of the SLEDAI score; flare was assessed using the SELENA flare instrument.